How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,246 results for

Emergency Medicine Treatment and Labor Act

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Preventing and Managing Infectious Diseases Among People who Inject Drugs in Ontario

who inject drugs o This element could include efforts to prevent or help people to stop injecting drugs, efforts to reduce the risk of infection (e.g., needle-exchange programs, safe consumption/injection sites, and opioid analgesic therapy) and enhancing education efforts for people who inject drugs (e.g., to minimize risk of infectious diseases, identify early symptoms of infectious diseases, and know where to seek treatment when needed). o Generally, the evidence for this element supported (...) >> Insight >> Action REPORT Injection drug use (IDU) has emerged as not only a pressing issue in Ontario given the spike in the overdose rate,(1) but also as a highly complex issue, given the need for coordinated responses that include those providing: • services and supports that reduce risk among people who inject drugs (PWID) (e.g., to prevent overdoses as well as the transmission of infectious diseases); • medical care (e.g., critical/emergency care providers and surgeons for treating life

2019 McMaster Health Forum

22. American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for Comprehensive Medical Care of Patients with Obesity

achieve weight loss or should it be used chronically in the treatment of obesity? 103 Q7.4. Are there differences in weight-loss drug efficacy and safety? 104 Q7.5. Should combinations of weight-loss medications be used in a manner that is not approved by the U.S. Food and Drug Administration? 108 Q8. Are there hierarchies of drug preferences in patients with the following disorders or characteristics? 108 Q8.1. Chronic kidney disease 108 Q8.2. Nephrolithiasis 109 Q8.3. Hepatic impairment 110 Q8.4 (...) recommendations allow for nuanced clinical decision-making that addresses real-world medical care of patients with obesity, includ- ing screening, diagnosis, evaluation, selection of therapy, treatment goals, and individualization of care. The goal is to facilitate high-quality care of patients with obesity and provide a rational, scientific approach to management that optimizes health outcomes and safety. (Endocr Pract. 2016;22:Supp3;1-205) Abbreviations: A1C = hemoglobin A1c; AACE = American Association

2016 American Association of Clinical Endocrinologists

23. Systematic review of needs for medical devices for ageing populations

Systematic review of needs for medical devices for ageing populations Systematic review of needs for medical devices for ageing populations Commissioned to the Australian Safety and Ef? cacy Register of New Interventional Procedures – Surgical (ASERNIP-S) by the World Health Organization (WHO) Department of Essential Medicines and Health Products World Health Organization 20 Avenue Appia CH-1211 Geneva 27 Switzerland Tel: +41 22 791 21 11 E-mail: medicaldevices@who.int http://www.who.int (...) ) and was prepared under the primary authorship of the Australian Safety and Efficacy Register of New Interventional Procedures – Surgical (ASERNIP-S) group of the Royal Australasian College of Surgeons. Funding for this project was provided by the Japanese Ministry of Health, Labour and Welfare. The aim of this project was to produce a report in the form of a systematic review for WHO on needs for medical devices for older people for five main health conditions and 19 specific topics. This report was produced

2015 ASERNIP-S

24. 12?step programs for reducing illicit drug use Full Text available with Trip Pro

and economic costs of illicit drug use motivate the strong political interest in treatment for illicit drug use and in identifying effective treatments. The main types of treatment are cognitive‐behavioural therapies, motivational enhancement, contingency management, psychoanalysis, network therapy and – the object of this review –12‐step programs (Galanter & Kleber, 2008). 1.2 DESCRIPTION OF THE INTERVENTION 12‐step approaches to the treatment of drug use are widespread in many countries. The oldest (...) enhancement therapy, relapse prevention). They concluded that 12‐step approaches were as effective as alternative approaches in terms of improving drinking consequences, and reduction of alcohol consumption. Ferri and colleagues did not explicitly exclude co‐dependence on illicit drugs, nor did they report whether participants, in the eighttrials that were included in the review, had comorbid substance dependence. Treatment effectiveness for comorbid participants treated for alcohol disorder might inform

2017 Campbell Collaboration

25. Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics

. Because most of the patients with PAH also had poor metabolic control, achieving good meta- bolic control may prevent PAH. If PAH is detected, pursuing effective treatment methods such as treatment with Bosentan and Sildenafil in consultation with a physician experienced in managing PAH is recommended. GENERAL MEDICAL CARE All patients with GSD should have a primary-care provider (“medical home”) specializing in pediatrics, adolescent, or internal medicine depending on the patient’s age (Box 7 (...) storage disease type I (GSD I) after reviewing the autopsy reports of two children whose livers and kidneys contained excessive amounts of Submitted 12 August 2014; accepted 12 August 2014; advance online publication 6 November 2014. doi:10.1038/gim.2014.128 Genet Med 00 00 2014 Genetics in Medicine 10.1038/gim.2014.128 ACMG Standards and Guidelines 00 00 12August2014 12August2014 © American College of Medical Genetics and Genomics 6November2014 Purpose: Glycogen storage disease type I (GSD I

2014 American College of Medical Genetics and Genomics

26. Medical Management of First-Trimester Abortion

other potential medical applications, including emergency contraception; cervical ripening and labor induction; and treatment of symptomatic uterine leiomyomas, endometriosis, Cushing syndrome, breast cancer, early pregnancy loss, and glaucoma ( , ). Misoprostol Misoprostol is an inexpensive prostaglandin E 1 analogue in a tablet form that is stable at room temperature. It is approved by the U.S. Food and Drug Administration (FDA) for oral administration to prevent gastric ulcers in individuals who (...) take antiinflammatory drugs on a long-term basis, and it is included in the FDA-approved labeling of mifepristone for use in abortion. It is used off-label in other regimens for abortion, labor induction, treatment of early pregnancy loss, prevention and treatment of postpartum hemorrhage, and cervical priming before uterine procedures, such as hysteroscopy ( ). Pharmacokinetic evaluations of misoprostol absorption when administered by various routes have been performed ( ). Routes that result

2014 American College of Obstetricians and Gynecologists

27. Short-acting ß2 agonists: restricted use for tocolysis in premature labour

2013 Salbutamol and terbutaline are short-acting β2 agonists (SABAs) with the obstetric indication of inhibition of premature labour. They are available in various formulations in the UK, including oral tablets, oral solutions, and parenterals (solutions for injection). In some European countries, these SABAs are also indicated at minimum doses and short duration of use for external cephalic version or emergency use in specified conditions. However, these are not licensed indications in the UK (...) Short-acting ß2 agonists: restricted use for tocolysis in premature labour Short-acting β2 agonists: restricted use for tocolysis in premature labour - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Short-acting β2 agonists: restricted use for tocolysis in premature labour Use has been restricted to 48 hours’ maximum parenteral use under specialist supervision, after a European safety review. Published 11 December 2014 From: Therapeutic area: , Contents Article date: November

2013 MHRA Drug Safety Update

28. Does Mednav, a Medical Navigation System, Aid Non-technical and Technical Skills in the Simulated Obstetric Emergency?

been developed called 'Mednav'. Mednav is a navigation device for the management of medical emergencies; developed at Chelsea and Westminster Hospital since 2010. This is a device which acts similar to a satellite navigation devices in the automobile industry navigating you from A to B, MedNav navigates the clinician from the unwell patient to the well patient. Condition or disease Intervention/treatment Phase Postpartum Hemorrhage, Device: MedNav Not Applicable Detailed Description: Potential (...) Posted : May 26, 2016 Last Update Posted : May 26, 2016 Sponsor: Chelsea and Westminster NHS Foundation Trust Information provided by (Responsible Party): Chelsea and Westminster NHS Foundation Trust Study Details Study Description Go to Brief Summary: It is well known that medical errors account for a large amount of patient harm within the hospital setting. This is a significant problem within the emergency context. A system that acts as a prompt, guide and scribe for the obstetric emergency has

2016 Clinical Trials

29. Emergency Medicine Treatment and Labor Act

Emergency Medicine Treatment and Labor Act Emergency Medicine Treatment and Labor Act Aka: Emergency Medicine Treatment and Labor Act , EMTALA From Related Chapters II. Background Emergency Medicine Treatment and Labor Act (EMTALA) was Enacted in U.S. in 1986 as part of COBRA Ensures access to emergency services regardless of ability to pay Applies to most hospitals in the United States (those that accept CMS payment) III. Criteria Includes an emergency medical screening to determine if a medical (...) Emergency Medicine Treatment and Labor Act Emergency Medicine Treatment and Labor Act Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4

2015 FP Notebook

30. Qualitative evidence on barriers to and facilitators of women’s participation in higher or growing productivity and male-dominated labour market sectors in low- and middle-income countries

Economic Empowerment and prominence within the 2030 Agenda for Sustainable Development. 1 A wide range of factors hinder women’s participation in the labour market, especially in higher productivity sectors that are male-dominated. Many countries around the world, either with international donor support or in response to domestic economic policy compulsions, are changing laws, regulations and policies to address these barriers. A trans-disciplinary literature has emerged in recent years that reflects (...) Qualitative evidence on barriers to and facilitators of women’s participation in higher or growing productivity and male-dominated labour market sectors in low- and middle-income countries 1 Qualitative evidence on barriers to and facilitators of women’s participation in higher or growing productivity and male-dominated labour market sectors in low- and middle-income countries SYSTEMATIC REVIEW, APRIL 2019 i The authors of this report are: H Elizabeth Peters (Urban Institute, Washington, DC

2019 EPPI Centre

31. Guidelines for the Administration of Electroconvulsive Therapy

that electroconvulsive therapy is a continually evolving practice. Conclusion: The guidelines provide up-to-date advice for psychiatrists to promote optimal standards of electroconvul- sive therapy practice. Keywords Guidelines, electroconvulsive therapy, monitoring, depressive disorders, schizophrenia 1 School of Medicine and Public Health, Faculty of Health and Medicine, The University of Newcastle, Australia, Callaghan, NSW, Australia 2 School of Psychiatry, Faculty of Health and Medical Sciences, The University (...) , 2013), and for the treatment of agitation and aggression in patients with dementia (Glass et al., 2017; Isserles et al., 2017; Manjola, 2015), though should only occur in these circumstances and for other emerging indica- tions in consultation with a psychiatrist with expertise in the use of ECT for such indications. There is also potential application of ECT in the treatment of severe Parkinsonism not responsive to medication with the on–off phenomenon and the occasional use of ECT for intractable

2019 American Psychiatric Association

32. Drugs for Rare Diseases: Evolving Trends in Regulatory and Health Technology Assessment Perspectives

, and Industry Incentives Enabling Legislation Criteria for Orphan Drug Designation Incentives for Pharmaceutical Industry US FDA Orphan Drug Act 1983 (and 1984, 1985, 1988, 1992 amendments The drug (expanded to include biologics, medical devices, medical foods) is indicated for treatment, diagnosis, or prevention of a disease or condition affecting fewer than 200,000 people in the US at the time of the orphan drug designation submission; or affects more than 200,000 people in the US but costs of developing (...) ; no satisfactory method of diagnosis, prevention or treatment of the condition concerned can be authorised, or, if such a method exists, the medicine must be of significant benefit to those affected by the condition.” 2 Japan’s Ministry of Health, Labour and Welfare “The number of patients who may use the drug should be less than 50,000 in Japan. The drugs should be indicated for the treatment of serious diseases, including difficult-to-treat diseases. In addition, they must be drugs for which there are high

2016 Canadian Agency for Drugs and Technologies in Health - Environmental Scanning

33. New Direct-acting Antiviral for Hepatitis C (Epclusa?

is associated with increased risk of unnecessary infection (Kcentra is partly produced from blood from non-donors). Another problem is that they are valuable medical resource that can be obtained only from blood donations. In case of emergency, they are not easily accessible. It also requires consent from patients (their families) prior to treatment. The MHLW denies causality between the drug and deaths, but this cannot be trusted [10-12]. High-risk patients are essentially the ones who need an effective (...) their pharmacologic therapies. ? The recent diabetic medicines are all costly. If the guidelines of the Japanese Diabetes Society are followed, high drug costs and medical costs would be needed. In addition, hypoglycemic attacks and cardiovascular diseases would occur frequently and life expectancy would be negatively affected, as well. On the other hand, the ACP guidance would reduce medical costs and improve health and life expectancy of patients with type 2 diabetes. ? Type 2 diabetes may develop and aggravate

2019 Med Check - The Informed Prescriber

34. Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy

for spontaneous neuraxial bleeding with these medications. 2.1 In patients scheduled to receive thrombolytic therapy, we recommend that the patient be queried and medical record reviewed for a recent history of lumbar puncture, spinal or epidural anesthesia, or ESI to allow appropriate monitoring. Guidelines detailing original contraindications to thrombolytic drugs suggest avoidance of these drugs for 10 days following puncture of noncompressible vessels (grade 1A). Remarks: There is no change (...) Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy Regional Anesthesia in the Patient Receiving Antithrombotic... : Regional Anesthesia and Pain Medicine You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page. Login No user account? Lippincott Journals Subscribers , use your username or email along with your password to log in. Remember me on this computer Register for a free account Registered

2018 American Society of Regional Anesthesia and Pain Medicine

35. 2018 IDSA Clinical Practice Guideline for the Management of Outpatient Parenteral Antimicrobial Therapy

appropriately early in treatment. The selected antimicrobial agent should have activity against the identified or presumptive causative pathogen(s), known distribution to the site of infection, and proven therapeutic efficacy in the infection being treated. Patient factors that may impact efficacy must be considered, including comorbidities, concomitant therapies (drug and non-drug), patient age, and organ function. Programmable infusion pumps and elastomeric devices (disposable balloons that push (...) . It does not offer recommendations on the treatment of specific infections. The reader is referred to disease- or organism-specific guidelines for such support. Executive Summary Outpatient parenteral antimicrobial therapy (OPAT) is defined as the administration of parenteral antimicrobial therapy in at least 2 doses on different days without intervening hospitalization. Recommendations made in the updated guideline for the prescription and management of OPAT are summarized below. The panel followed

2018 Infectious Diseases Society of America

36. Interventions to improve the labour market outcomes of youth: A systematic review of training, entrepreneurship promotion, employment services and subsidized employment interventions Full Text available with Trip Pro

and valued qualifications 7. Adequate economic, social, institutional and administrative conditions are in place Technical training programmes are popular in development cooperation because many developing countries experience a skills mismatch between their labour force and emerging segments of their economies. However, pure training programmes have not proven to be particularly successful in many contexts ( ). Therefore, most recent programmes tend to combine skills training with other types (...) outcomes of young people. The evaluation found that the reinforced counselling programme had a positive impact on the employment status of young jobseekers eight months after assignment to the treatment group, compared to untreated jobseekers. However, these positive effects appeared to have come partly at the expense of eligible workers who did not benefit from the programme, particularly in labour markets where they were competing mainly with other educated workers and in weak labour markets. Sources

2017 Campbell Collaboration

37. Vocational and business training to improve women's labour market outcomes in low? and middle?income countries: a systematic review Full Text available with Trip Pro

Vocational and business training to improve women's labour market outcomes in low? and middle?income countries: a systematic review Vocational and business training to improve women's labour market outcomes in low‐ and middle‐income countries: a systematic review - Chinen - 2017 - Campbell Systematic Reviews - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search within Search term Search term SYSTEMATIC REVIEW Open Access (...) Vocational and business training to improve women's labour market outcomes in low‐ and middle‐income countries: a systematic review Corresponding Author E-mail address: Corresponding author Thomas de Hoop American Institutes for Research USA E‐mail: Corresponding Author E-mail address: Corresponding author Thomas de Hoop American Institutes for Research USA E‐mail: First published: 21 December 2017 Citations: Linked article: . Give access Share full text access Please review our and check

2017 Campbell Collaboration

38. Brilinta (ticagrelor) Tablets - medical review

might argue that the individual SUSARs as in these examples are impossible to interpret individually. However, all of them fall into the “(C)” category described in the CFR: “(C) An aggregate analysis of specific events observed in a clinical trial (such as known consequences of the underlying disease or condition under investigation or other events that commonly occur in the study population independent of drug therapy) that indicates those events occur more frequently in the drug treatment group (...) Brilinta (ticagrelor) Tablets - medical review CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 022433Orig1s000 MEDICAL REVIEW(S) DIVISION OF CARDIOVASCULAR AND RENAL PRODUCTS Complete Response Review Addendum Sponsor Safety Reporting Submissions: NDA 22-433 and IND 65,808 SD 632 Drug: ticagrelor (Brilinta™) Indication: reduce the rate of thrombotic events in patients with acute coronary syndromes (ACS) Sponsor: AstraZeneca Review date: June 8, 2011 Reviewer: Thomas A. Marciniak, M.D

2011 FDA - Drug Approval Package

39. Preterm labour and birth

://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 10 of 27likelihood of birth within 48 hours. Act on the results as follows: if cervical length is more than 15 mm, explain to the woman that it is unlikely that she is in preterm labour and: think about alternative diagnoses discuss with her the benefits and risks of going home compared with continued monitoring and treatment in hospital advise her that if she does decide to go home, she should return if symptoms suggestive of preterm labour (...) persist or recur if cervical length is 15 mm or less, view the woman as being in diagnosed preterm labour and offer treatment as described in sections 1.8 and 1.9. 1.7.5 Consider fetal fibronectin testing as a diagnostic test to determine likelihood of birth within 48 hours for women who are 30 +0 weeks pregnant or more if transvaginal ultrasound measurement of cervical length is indicated but is not available or not acceptable. Act on the results as follows: if fetal fibronectin testing is negative

2015 National Institute for Health and Clinical Excellence - Clinical Guidelines

40. Occupational Therapy for people Undergoing total hip replacement

and successful interventions in the whole of medical practice. The success of hip replacement is entirely dependent upon a multidisciplinary team approach, with occupational therapy being a core part of its success. The updated guidance reflects changes in practice and in particular the requirement for reduction in length of stay. The trend for patients undergoing hip arthroplasty at younger ages continues, as does the increasing numbers of total hip replacements being performed year on year. National (...) then be developed and a treatment plan jointly agreed.The occupational therapy role 12 Occupational therapy for adults undergoing total hip replacement The home situation is discussed from the perspective that the service user is expert in this domain and their specific needs and choices. The service user can inform the occupational therapist about specific heights of their furniture (chair, bed and toilet) so that equipment may be prescribed to compensate for lack of function, or to enable activities

2018 British Association of Occupational Therapists

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>